Walgreens is supporting the more than 56 million patients in the Medicare network that may be eligible for GLP-1 medications through the Medicare GLP-1 Bridge programme. Walgreens pharmacists will help eligible Medicare patients navigate the new programme at nearly 8,000 stores across the US. To get started, patients should speak with their healthcare provider about whether they may be eligible for the Medicare Bridge programme.
The Medicare Bridge programme is a new nationwide initiative from the Centers for Medicare & Medicaid Services (CMS) designed to help eligible Medicare beneficiaries access FDA-approved GLP-1 medications for weight management at a predictable and more affordable US$50 monthly copay for those who qualify. The programme launches July 1, 2026, and runs through December 31, 2027.
“Walgreens’ trusted pharmacists are trained to help patients navigate eligibility requirements and stay on track with treatment,” said Rick Gates, Chief Pharmacy Officer, Walgreens. “Every patient’s weight loss journey is different, and our pharmacists are here to help from the moment a patient first considers a GLP-1.”
